Related Experiment Video
Updated: Apr 3, 2026
Implantation of Electroencephalogram and Electrocardiogram Telemetry Devices in Neonatal Rabbit Kits
Published on: February 28, 2025
Transplacental Administration of Rosiglitazone Attenuates Hyperoxic Lung Injury in a Preterm Rabbit Model
Jute Richter1, Jaan Toelen, Taro Nagatomo
1Department of Development and Regeneration, Organ System Cluster, Faculty of Medicine, KU Leuven, Leuven, Belgium.
Insights
Prenatal rosiglitazone treatment in rabbits reduced lung injury in preterm infants exposed to high oxygen. This intervention promoted lung development and improved respiratory function in newborns.
Area of Science:
- Neonatology
- Pulmonology
- Developmental Biology
Background:
- Advances in perinatal care increase survival of extremely premature infants.
- Immature lungs of premature infants are susceptible to chronic lung injury from respiratory support.
- Hyperoxia-induced lung injury is a significant cause of mortality and morbidity in neonates.
Purpose of the Study:
- To investigate the efficacy of prenatal rosiglitazone administration in preventing hyperoxia-induced lung injury.
- To evaluate the impact of rosiglitazone on lung maturation and respiratory function in preterm neonates.
Main Methods:
- Pregnant rabbits received rosiglitazone or saline 48 and 24 hours before preterm delivery.
- Newborn pups were exposed to normoxia or hyperoxia (>95% O2).
- Lung function, tissue damping, and expression of key proteins (VEGF, FLK-1, SP-B) were assessed at 1 hour, 24 hours, and 7 days post-delivery.
Main Results:
- Rosiglitazone administration significantly decreased lung tissue damping (resistance) by day 7.
- Increased expression of vascular endothelial growth factor (VEGF), fetal liver kinase 1 (FLK-1), and surfactant protein B (SP-B) was observed immediately after birth.
- Rosiglitazone-exposed pups exhibited more mature lung parenchymal architecture by day 7.
Conclusions:
- Prenatal maternal administration of rosiglitazone attenuates neonatal hyperoxic lung injury in a preterm rabbit model.
- Rosiglitazone treatment promotes pulmonary parenchyma maturation in preterm neonates.
- This strategy holds potential for improving outcomes in extremely premature infants at risk for lung injury.
Introduction:
Continuous improvements in perinatal care have allowed the survival of increasingly more prematurely born infants. The establishment of respiration in an extremely immature yet still developing lung results in chronic lung injury with significant mortality and morbidity. We experimentally evaluated a novel medical strategy to prevent hyperoxia-induced lung injury by prenatal rosiglitazone.
Materials And Methods:
Pregnant rabbits were injected with saline or rosiglitazone (3 mg/kg) 48 and 24 h prior to preterm delivery at 28 days of gestation (term = 31 days). The pups were held in normoxia (21% O2) or hyperoxia (>95% O2), and assessment was done at three different time points (1 h, 24 h and 7 days).
Results:
The administration of rosiglitazone resulted in a significant decrease in tissue damping (resistance) on day 7. Furthermore, significantly increased expression of vascular endothelial growth factor, fetal liver kinase 1 and surfactant protein B immediately after delivery was noted by immunohistochemistery. On day 7, there was a more mature lung parenchymal architecture in rosiglitazone-exposed pups.
Discussion:
In a preterm rabbit model, prenatal maternal administration of rosiglitazone attenuates neonatal hyperoxic lung injury and results in a more mature pulmonary parenchyma.
